Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celltech Codeprex Approved For 12-Hour Cough Suppression

This article was originally published in The Pink Sheet Daily

Executive Summary

Celltech expects the codeine-based antitussive to hit retail pharmacy shelves by the fourth quarter. The extended-release formulation eliminates the need for middle of the night dosing, the company says.

You may also be interested in...

Celltech Finds CDP-870 Partner In UCB; BLA Filing Expected By 2007

The licensing agreement gives Celltech a means through which to commercialize the TNF inhibitor should the companies' proposed $2.7 bil. merger agreement fall through. UCB/Celltech will be fifth largest biotech company worldwide.

Bristol To Name New R&D Head Shortly

Senior VP-Global Clinical & Pharmaceutical Development Elliott Sigal is acting president of Bristol-Myers Squibb’s research institute following the death of James Palmer.

Chiron Fluvirin Remediation Plan Design Underway

The four-pronged plan will address “bio-burden,” manufacturing techniques, quality systems and execution, CEO Pien says. Chiron has met twice with U.K. authorities and hopes to realize similar progress with FDA soon.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts